创新药年内出海交易总额超455亿美元，港股创新药ETF（159567）盘初上涨，机构：创新药景气度有望持续

Group 1 - The Hong Kong stock market opened strong on the first trading day of June, with pharmaceutical stocks rising, particularly the Hong Kong Innovative Drug ETF (159567) which increased by 0.22% [1] - At least six domestic innovative drug companies announced BD transaction orders in May, indicating a trend of cross-border cooperation between Chinese and foreign pharmaceutical companies [1] - The total amount of innovative drug transactions overseas has reached $45.5 billion since the beginning of 2025, with upfront payments amounting to $2.2 billion, suggesting a potential record high for the year [1] Group 2 - Hansoh Pharmaceutical announced a licensing agreement with Regeneron Pharmaceuticals for the global exclusive rights to develop, produce, and commercialize HS-20094, excluding mainland China, Hong Kong, and Macau, with an upfront payment of $80 million [2] - The National Medical Products Administration has approved 11 new innovative drugs for market entry, with two more under priority review, which is expected to support the performance growth of related companies [2] - The pharmaceutical industry is anticipated to experience valuation recovery in 2025 due to factors such as innovative drug transactions, optimization of domestic procurement policies, and recovery of medical device tenders [2]